Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00331513
Status:
COMPLETED
Last Update Posted:
2013-09-30
First Post:
2006-05-30
Brief Title:
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Secondary Myelodysplastic Syndromes |
| Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome |
| Adult Acute Myeloid Leukemia With 11q23 MLL Abnormalities |
| Adult Acute Myeloid Leukemia With Inv16p13q22 |
| Adult Acute Myeloid Leukemia With t1517q22q12 |
| Adult Acute Myeloid Leukemia With t1616p13q22 |
| Adult Acute Myeloid Leukemia With t821q22q22 |
| Adult Acute Promyelocytic Leukemia M3 |
| Blastic Phase Chronic Myelogenous Leukemia |
| MyelodysplasticMyeloproliferative Neoplasm Unclassifiable |
| Previously Treated Myelodysplastic Syndromes |
| Recurrent Adult Acute Lymphoblastic Leukemia |
| Recurrent Adult Acute Myeloid Leukemia |
| Relapsing Chronic Myelogenous Leukemia |
| Secondary Acute Myeloid Leukemia |
Keywords: